Email updates

Keep up to date with the latest news and content from Pediatric Rheumatology and BioMed Central.

This article is part of the supplement: Proceedings of 18th Pediatric Rheumatology European Society (PReS) Congress

Open Access Open Badges Oral presentation

Analysis of growth in female patients with pediatric-onset systemic lupus erythematosus

NC Mak1*, C Carbone2, LS Lim2, DM Levy2, ED Silverman2 and S Kamphuis12

Author Affiliations

1 Sophia’s Children Hospital, Erasmus MC Rotterdam, Netherlands

2 The Hospital for Sick Children, Toronto, Canada

For all author emails, please log on.

Pediatric Rheumatology 2011, 9(Suppl 1):O19  doi:10.1186/1546-0096-9-S1-O19

The electronic version of this article is the complete one and can be found online at:

Published:14 September 2011

© 2011 Mak et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Systemic Lupus Erythematosus (SLE) is a lifelong disease characterised by multi-organ involvement and autoantibodies. It is assumed that growth impairment is common in pediatric-onset SLE (pSLE), but studies reporting on the frequency and characteristics of growth abnormalities in pSLE are lacking.


To analyse growth in female patients with pSLE and examine its relationship to disease characteristics and treatment.


Prospectively collected digital growth curves and menarche status of an inception cohort of 196 female patients with pSLE diagnosed <16 years and a minimal disease duration of 3 years were analysed. Abnormal growth was defined as i) one or more periods of growth arrest (<2 cm) lasting minimal 6 months, ii) more than one growth curve percentile difference between height at diagnosis and at any follow up visit, or iii) < 2 cm growth after menarche. 67 patients were not further analyzed as they had reached final height prior to diagnosis of pSLE.


58/129 (45%) pSLE patients with growth potential had abnormal growth. The median growth curve percentile at diagnosis (50th) was significantly different from the percentile at last follow up (10th) in these patients with abnormal growth (p<0.001). Patients with abnormal growth were diagnosed significantly younger than patients with normal growth (9.4±2.8 versus 11.6±2.6 years, p<0.001). 90% of these patients showed period(s) of growth arrest, whereas 10% showed a gradual decline in growth only. The median height of the 36 patients with abnormal growth having reached age 16 years (presumed final height) was significantly lower compared to the height of patients diagnosed after 16 years (154.8±8.6 versus 161±6.1cm, p<0.001). Ethnicity, disease activity over time and cumulative medication use are currently being tested for their potential relation to growth impairment.


Growth was impaired in approximately half of female pSLE patients and may lead to abnormally low final height. Abnormal growth was characterized by periods of normal growth and growth arrest rather than gradual decline in growth, likely related to disease flares and/or treatment.